Skip to Main Content

Author Details

Donald Small
Johns Hopkins University School of Medicine
1977
117
52
PMIDPaper TitleJournal TitlePublished Year
37147424NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia.Leukemia2023
37147424NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia.Leukemia2023
34024909FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.Signal Transduct Target Ther2021
33914060Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.Blood Adv2021
33846544Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.Leukemia2021
33623141FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.Leukemia2021
34024909FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.Signal Transduct Target Ther2021
34589716A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors.Blood Cancer Discov2021
33623141FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.Leukemia2021
33846544Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.Leukemia2021
33914060Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.Blood Adv2021
34589716A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors.Blood Cancer Discov2021
31408245A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor.Genes Chromosomes Cancer2020
31408245A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor.Genes Chromosomes Cancer2020
30975911FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.Haematologica2019
30975911FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.Haematologica2019
30450160Knock-in of the <i>Wt1</i> R394W mutation causes MDS and cooperates with <i>Flt3/ITD</i> to drive aggressive myeloid neoplasms in mice.Oncotarget2018
30450160Knock-in of the <i>Wt1</i> R394W mutation causes MDS and cooperates with <i>Flt3/ITD</i> to drive aggressive myeloid neoplasms in mice.Oncotarget2018
30250637Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.Oncotarget2018
30250637Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.Oncotarget2018
27748370DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.Leukemia2017
28923853Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.Cancer Res2017
29179430DOCK2: A novel FLT3/ITD leukemia drug target.Oncotarget2017
28077790FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Oncotarget2017
27748370DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.Leukemia2017
27908881Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.Blood2017
28077790FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Oncotarget2017
29179430DOCK2: A novel FLT3/ITD leukemia drug target.Oncotarget2017
28923853Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.Cancer Res2017
27908881Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.Blood2017
27103744All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.Blood2016
30302214Potential role for all-<i>trans</i> retinoic acid in nonpromyelocytic acute myeloid leukemia.Int J Hematol Oncol2016
27103744All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.Blood2016
27636998Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.Oncotarget2016
30302214Potential role for all-<i>trans</i> retinoic acid in nonpromyelocytic acute myeloid leukemia.Int J Hematol Oncol2016
27636998Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.Oncotarget2016
24227820Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.Blood2014
25333254Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.Oncotarget2014
24408321TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.Blood2014
24440599Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.Cell Stem Cell2014
24184354NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.Exp Hematol2014
24227820Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.Blood2014
24747944Correlated miR-mRNA expression signatures of mouse hematopoietic stem and progenitor cell subsets predict "Stemness" and "Myeloid" interaction networks.PLoS One2014
25060518FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Cancer Res2014
25333254Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.Oncotarget2014
25060518FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Cancer Res2014
24747944Correlated miR-mRNA expression signatures of mouse hematopoietic stem and progenitor cell subsets predict "Stemness" and "Myeloid" interaction networks.PLoS One2014
24408321TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.Blood2014
24440599Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.Cell Stem Cell2014
24184354NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.Exp Hematol2014
  • 1 - 50 of 234

Recommended Authors

Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Career Start Year 2017
Number of shared co-authors 5
Samuel B Luty
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 0
Kevin Watanabe-Smith
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2010
Number of shared co-authors 1
Catherine C Smith
University of California San Francisco
Career Start Year 2009
Number of shared co-authors 6
Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2009
Number of shared co-authors 5
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 2
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 7
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 3
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 4
Aniruddha J Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2004
Number of shared co-authors 1
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 2
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 10
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 1
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 6
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 4
Shinichiro Takahashi
Tohoku Medical and Pharmaceutical University Hospital.
Career Start Year 1998
Number of shared co-authors 0
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 0
Michael W Deininger
University of Utah Huntsman Cancer Institute
Career Start Year 1997
Number of shared co-authors 8
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 4
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1993
Number of shared co-authors 4
Timothy A Graubert
Massachusetts General Hospital
Career Start Year 1993
Number of shared co-authors 4
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 6
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 6
Ravi Bhatia
University of Alabama at Birmingham
Career Start Year 1992
Number of shared co-authors 10
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 9
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 4
Scott A Armstrong
Boston Children's Hospital
Career Start Year 1990
Number of shared co-authors 9
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 14
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 13
Brian J Druker
Oregon Health & Science University
Career Start Year 1978
Number of shared co-authors 12

Collaborators

Mark J Levis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Co-authored papers 43
Li Li
Johns Hopkins University School of Medicine
Co-authored papers 31
Patrick Brown
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Co-authored papers 22
Curt I Civin
Center for Stem Cell Biology & Regenerative Medicine and.
Co-authored papers 12
Kyu-Tae Kim
Ajou University
Co-authored papers 10
Obdulio Piloto
Entopsis Inc.
Co-authored papers 9
Bert Vogelstein
Co-authored papers 5
Peter A Calabresi
Johns Hopkins University School of Medicine
Co-authored papers 4
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 4
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Co-authored papers 3
Dale L Ludwig
Co-authored papers 3
Feyruz V Rassool
University of Maryland Greenebaum Comprehensive Cancer Center
Co-authored papers 3
Jorge Cortes
Georgia Cancer Center
Co-authored papers 3
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Mignon L Loh
University of Washington
Co-authored papers 2
Christine A Pratilas
Johns Hopkins University School of Medicine
Co-authored papers 2
David M Loeb
Children's Hospital at Montefiore.
Co-authored papers 2
Jerry L Spivak
The Johns Hopkins University School of Medicine
Co-authored papers 2
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 2
Todd A Alonzo
Keck School of Medicine, University of Southern California
Co-authored papers 2
Ian M Kaplan
Adaptive Biotechnologies Corp
Co-authored papers 2
Kristin Baird
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Stephen P Hunger
Children's Hospital of Philadelphia
Co-authored papers 2
Meenakshi Devidas
St Jude Children's Research Hospital
Co-authored papers 2
Linzhao Cheng
Johns Hopkins University School of Medicine
Co-authored papers 2
Christopher D Gocke
Johns Hopkins University School of Medicine
Co-authored papers 2
Soheil Meshinchi
Fred Hutchinson Cancer Research Centre
Co-authored papers 2
Peili Chen
University of Chicago
Co-authored papers 2
Sebastien Morisot
Co-authored papers 1
Yuelin J Zhu
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Release 1.2